Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice
Background: Recent clinical trials indicate that sodium–glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in myocardial infarction (MI) patients, but the underlying mechanisms remain unknown. As arrhythmia often occurs during myocardial infarction, it is the main cause of de...
Main Authors: | Genlong Xue, Xiaolei Yang, Ge Zhan, Xin Wang, Jinghan Gao, Yong Zhao, Xinying Wang, Jiatian Li, Zhenwei Pan, Yunlong Xia |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.988408/full |
Similar Items
-
Benefits of SGLT2 inhibitors in arrhythmias
by: Jinghan Gao, et al.
Published: (2022-10-01) -
Highly selective sodium glucose cotransporter type 2 inhibitor empagliflozin neuroprotective potential in chronic brain dyscirculation
by: Оksana S. Fuks, et al.
Published: (2023-07-01) -
Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review
by: Sopak Supakul, et al.
Published: (2022-06-01) -
Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis
by: Marta Brandão Calçada, et al.
Published: (2021-04-01) -
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
by: Ellen Vercalsteren, et al.
Published: (2024-02-01)